PD-0458: AFP response as a predictor of clinical outcome after stereotactic body radiotherapy (SBRT) for advanced HCC  by Chiang, C.L. et al.
S178  2nd ESTRO Forum 2013	
with short course hypofractionated radiotherapy (RT) were included in 
this study. Pre-operative treatment with RT was followed by a total 
mesorectal excision (TME) within 3 days after the last RT fraction. For 
each patient, a FDG-PET-CT scan was performed prior to the start of 
treatment. The tumor was automatically delineated from the PET-
images using SUV-thresholding, with the threshold depending on the 
tumor-to-background signal ratio. The volume of the PET-based tumor 
contour was validated by pathological examination of the resected 
specimen. For this validation, the resected specimen was sliced into 5 
mm slices and each slice was photographed. On the photographs, the 
tumor was manually delineated by the pathologist. The tumor volume 
was calculated by multiplying the tumors surface area with the slice 
thickness of 5 mm. Automatic delineation with other methods, 
including watershed based clustering, will be presented. 
Results: Automatic SUV-threshold based tumor delineation resulted in 
an average tumor volume of 16.2±11.3 cm3 (range: 7.7 to 38.7 cm3), 
whereas pathological examination of the resected specimens resulted 
in an average tumor volume of 16.0±11.5 cm3 (range: 7.8 to 36.5 cm3). 
The average volume difference was 2±2.0 cm3 (range: -2.2 to 3.0 
cm3). A correlation coefficient of 0.964 (p<0.001) was found when 
correlating the tumor volumes resulting from PET-analysis and 
pathological examination. 
Conclusions: The strong correlation between the tumor volumes 
resulting from SUV-thresholding of PET-images and pathological 
examination of the surgical specimen demonstrates the accuracy of 
automatic PET-based tumor delineation based on SUV-thresholding for 
patients diagnosed with rectal cancer. This unique 3D dataset will be 
used as golden standard for the comparison of multiple PET-based 
automatic segmentation algorithms. 
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Purpose/Objective: The clinical utility of alpha-fetoprotein (AFP) as a 
predictor of treatment outcome in patients with advanced HCC 
receiving stereotactic body radiotherapy (SBRT) has been poorly 
defined. We aimed to study the clinical value of AFP response in an 
attempt to validate it as a surrogate serologic end point. 
Materials and Methods: We analyzed the prospectively collected data 
of 53 locally advanced HCC patients with elevation of AFP (>20) 
received individualized hypofractionated radiotherapy using 
stereotactic body radiotherapy (SBRT) technique between 2006 and 
2011. AFP response defined as >50% decrease from baseline, 3 months 
after the completion of SBRT. Radiological response rate was assessed 
by CT scan using RECIST criteria.  
Results: Median follow-up time was 11.2 months. Patients' 
characteristics were as follows: Median age (62 years, range: 36-86); 
Male/ female (n= 44/9 respectively); Child-Pugh class A/B (n= 45/8 
respectively); and portal vein thrombosis (n=23). Individualized 
hypofractionated radiotherapy using SBRT technique was given at 4Gy 
per fraction, range from 5-10 fractions, with the median dose of 32Gy 
was delivered. The overall response rate was 39.6%. The median 
overall survival (OS) and progression free survival (PFS) was 11.2 
months and 5.4 months respectively. AFP responders (n= 22) had 
better objective response rate than AFP non-responders (n=31) after 
SBRT (59.1 vs. 25.8%; P=0.01). Median OS rate was longer in AFP 
responders (17.9 vs 9.0 months, p=0.02). Median PFS rate was also 
longer in AFP responder than AFP non-responders although it was not 
statistically significant. (PFS, 7.0 vs 5.1 months, p= 0.18). In 
multivariate analysis, AFP response was independent factor affecting 
OS (hazard ratio, 2.46; 95% CI, 1.07 to 5.68; p=0.035). Of the 29 
patients with radiological stable disease (SD), AFP responders (n=9) 
had a better 1-year survival rate than AFP non-responders (n=20) 
(66.7% vs 31.9%, p=0.049). 
Figure 1. Overall survival (OS) of AFP responders and AFP non-
responders 
 
Conclusions: AFP response is useful in predicting prognosis and 
treatment response in patients with advanced HCC received SBRT. 
Incorporation of AFP response into the criteria of evaluating the 
outcome of SBRT should be considered. Additional treatment may 
require in the AFP non-responders. 
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Purpose/Objective: To investigate the possible benefit deriving from 
whole pelvis radiotherapy (WPRT) in combination with high-dose 
salvage radiotherapy (HDSRT) in the salvage treatment of node-
negative patients experiencing a biochemical recurrence (BR) after 
radical prostatectomy (RP) and pelvic lymphoadenectomy. 
Materials and Methods: From 1998 to 2008, 208 node-negative 
(median 11 LN) patients (pts) underwent HDSRT at 1.8 Gy/fraction to 
the prostatic bed (PB) only (n=138, median dose 73.8 Gy) or to WPRT 
(n=70, median dose 50.4 Gy) followed by a boost to PB (median dose 
75.6 Gy). All pts underwent 3DCRT technique except for 28 who 
received WPRT-IMRT followed by a 3DCRT boost to PB. 
Patients characteristics were comparable in terms of preoperative 
PSA, pT, surgical margins, Gleason score (GS), median time to BR 
after RP (overall 21.5 months), median PSA doubling time (PSADT, 
overall 8.9 months), PSA at SRT (PSA@SRT, overall 0.70 ng/mL) and 
fraction of pts receiving neoadjuvant (NAD) or adjuvant androgen 
deprivation (AAD) in addition to SRT. The 2 groups differed 
significantly in terms of median follow-up (FU, 102 vs 73 months, 
owing to the gradual introduction of WPRT over time), fraction of 
biopsy confirmed local relapse (49% vs 31%), length of AAD (10 vs 15 
months) and median RT dose (73.8 vs 75.6 Gy) in PB vs WPRT+PB 
group, respectively.  
Results: After a median FU of 87 months, WPRT+PB resulted in a 
significant improvement of 7-year biochemical relapse-free survival 
(bRFS) when compared to PB only both in the overall population (86 vs 
67%, p=0.02) and in the subset of the 134 pts with a PSA@SRT ≤1 
ng/mL (90 vs 69%, p=0.02). The other factor predictive of improved 
bRFS at univariate analysis (UA) in both subgroups was RT dose (p-
value always <0.0001, most informative cut-off <73.8 Gy in both 
cohorts). Radiation doses ≥75.6 Gy resulted in improved 7-year bRFS 
both in the overall population (87% vs 63%, p<0.0001) and in pts with 
PSA@SRT ≤1 ng/mL (85% vs 65%, p=0.002). In the overall population, 
pT and PSADT (but not NAD nor AAD) were also significant predictors 
of bRFS at UA. At multivariate analysis, in the overall population 
PSA@SRT, RT dose ≤73.8 Gy, PB only irradiation and GS 7-10 (and in 
the subset with PSA@SRT ≤1 ng/mL, PB only RT and and GS ≥8) 
independently predicted treatment failure. Overall, HDSRT resulted in 
only mild acute and late genitourinary (GU) and gastrointestinal (GI) 
toxicity (TOX), without significant differences between WPRT+PB or 
PB subgroups. Of note, WPRT resulted in a doubling of acute intestinal 
G2 TOX (15 vs 7%), a finding which disappeared when only pts treated 
